(Individual results may vary)
Fasting insulin and HOMA-IR (a measure of insulin resistance) decreased substantially at all active doses, with the greatest reductions at 8mg and 12mg
These gastrointestinal symptoms are usually mild to moderate and often decrease as the treatment continues
Risks of Switching From Semaglutide to Tirzepatide Adverse Effects : Both medications may have commonly reported side effects which are generally gastrointestinal disturbances (nausea, vomiting, diarrhea, stomach upset) and injection-site reactions (1,2,4,5)
A qualified clinician will monitor your progress, evaluate any side effects, and determine the safest dose for your specific biological needs
Thighs, both inner and outer, can show localized sag when leg fat decreases